Going public, Provention Bio looks to tackle immune-mediated diseases

Shares in Oldwick, N.J.-based Provention Bio began trading today following the close of its $64 million initial public offering last week.

The biopharmaceutical company, lead by co-founder & CEO Ashleigh Palmer, is developing a number of products that aim to prevent or stop the spread of immune-mediated diseases, including Lupus, Crohn’s disease and Type I diabetes.

Provention Bio’s strategy is to find drugs that have been developed by other pharmaceutical companies and take them through the clinical development process. But Palmer draws a clear distinction – the company is not “sifting through the trashcan of big pharma.”

Get the full story at our sister site, Drug Delivery Business News.

The post Going public, Provention Bio looks to tackle immune-mediated diseases appeared first on MassDevice.

from MassDevice https://ift.tt/2JRpNFA